ArticleJournal for immunotherapy of cancer2023

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.

Richard S P Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.